Literature DB >> 11954663

Daily low-dose administration of growth hormone secretagogue stimulates pulsatile growth hormone secretion and elevates plasma insulin-like growth factor-1 levels in pigs.

K Malmlöf1, M K Bauer, P B Johansen, M Ankersen, J D Veldhuis.   

Abstract

Repeated administration of growth hormone secretagogues (GHSs) has proven to be a delicate matter owing to development of tolerance. The aim of the present study was to define conditions during which the responsiveness to the orally active NN703 was maintained over several days. Growing pigs were fitted with stomach and vascular catheters, permitting unstressed intragastric administrations and blood sampling. NN703 or vehicle was administered once daily. When NN703 was given at a dose of 18 mg/kg, there was a massive acute increase in plasma growth hormone (GH) levels, but this was only seen on the first day of administration. A dose of 1.8 mg/kg did not cause a significant acute increase in plasma GH concentrations, whereas stimulation of pulsatile GH release was sustained over a 4-d period. During the first 7 h following injection of vehicle, the area under the curve of plasma GH was 1211+/-144 (microg/[L x 7 h]), but increased to 1770+/-269 and 1824+/-198 (microg/[L x 7 h]) on the first and fourth day of NN703 administration, respectively. Deconvolution analysis of the 7-h profiles revealed that the GH mass per burst as well as the GH burst amplitude were significantly (p < 0.001) increased during treatment with NN703, which led to an increase in pulsatile GH secretion rate (p < 0.001). Insulin-like growth factor-1 plasma concentrations increased steadily during NN703 administration (p < 0.01) and decreased after termination of treatment. The sustained increase in GH pulsatility observed with low-dose NN703 treatment suggests that development of tolerance to this GHS may be obviated by minimization of dose.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11954663     DOI: 10.1385/ENDO:16:3:195

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  33 in total

1.  Ghrelin elicits a marked stimulatory effect on GH secretion in freely-moving rats.

Authors:  L M Seoane; S Tovar; R Baldelli; E Arvat; E Ghigo; F F Casanueva; C Dieguez
Journal:  Eur J Endocrinol       Date:  2000-11       Impact factor: 6.664

2.  High plasma growth hormone (GH) levels inhibit expression of GH secretagogue receptor messenger ribonucleic acid levels in the rat pituitary.

Authors:  R Nass; J Gilrain; S Anderson; B Gaylinn; A Dalkin; R Day; M Peruggia; M O Thorner
Journal:  Endocrinology       Date:  2000-06       Impact factor: 4.736

3.  Hypothalamic growth hormone secretagogue-receptor (GHS-R) expression is regulated by growth hormone in the rat.

Authors:  P A Bennett; G B Thomas; A D Howard; S D Feighner; L H van der Ploeg; R G Smith; I C Robinson
Journal:  Endocrinology       Date:  1997-11       Impact factor: 4.736

4.  Deconvolution analysis of hormone data.

Authors:  J D Veldhuis; M L Johnson
Journal:  Methods Enzymol       Date:  1992       Impact factor: 1.600

5.  Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children.

Authors:  B Klinger; A Silbergeld; R Deghenghi; J Frenkel; Z Laron
Journal:  Eur J Endocrinol       Date:  1996-06       Impact factor: 6.664

6.  Pharmacological characterisation of a new oral GH secretagogue, NN703.

Authors:  B S Hansen; K Raun; K K Nielsen; P B Johansen; T K Hansen; B Peschke; J Lau; P H Andersen; M Ankersen
Journal:  Eur J Endocrinol       Date:  1999-08       Impact factor: 6.664

7.  Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms.

Authors:  N Shah; W S Evans; C Y Bowers; J D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  1999-06       Impact factor: 5.958

8.  Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a).

Authors:  J Svensson; J O Jansson; M Ottosson; G Johannsson; M R Taskinen; O Wiklund; B A Bengtsson
Journal:  J Clin Endocrinol Metab       Date:  1999-06       Impact factor: 5.958

9.  Chronic central infusion of growth hormone secretagogues: effects on fos expression and peptide gene expression in the rat arcuate nucleus.

Authors:  A R Bailey; M Giles; C H Brown; P M Bull; L P Macdonald; L C Smith; R G Smith; G Leng; S L Dickson
Journal:  Neuroendocrinology       Date:  1999-08       Impact factor: 4.914

10.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.